[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prep-adherence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prep-adherence":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,49,79,116,130,157,181],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053662","linking-youth-to-pre-exposure-prophylaxis-prep-services-100053662",false,"NCT07438041","Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services","Linking Youth to Pre-Exposure Prophylaxis (PrEP) Services (LYPS): An Innovative Mobile Delivery and Mobile Health (mHealth) Intervention to Optimize PrEP Adherence and Persistence","LYPS","Inclusion Criteria:\n\n* Age 13-24 years, inclusive;\n* Reports anal or vaginal sex in the past year;\n* Is not living with HIV;\n* Weighs at least 35 kilograms (77 pounds);\n* Willing to receive PrEP care from a provider at a participating SC either in the clinic or at one of the designated places in the community being offered by the SC SC;\n* Has an Android-based smartphone or iPhone;\n* Has fluency in English (able to read, speak, and understand English); and\n* Willing to provide informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Has counter-indications for PrEP according to guidelines and approved local label;\n* Has any clinically significant systemic disease (including but not limited to significant or uncontrolled liver disease, gastrointestinal disease, kidney disease, thyroid disease, osteoporosis, or bone disease) or diabetes;\n* Any other medical, behavioral, or other conditions that, in the opinion of the SC project lead or designee, could interfere with adherence to study procedures or compromise interpretation of study results;\n* Concurrent participation in ATN 166, ATN 170, or any other clinical trial providing HIV medications (PrEP, vaccine, etc.) or currently receiving any PrEP-adherence or persistence behavioral intervention; or\n* Is currently incarcerated or pending incarceration.",true,"ALL","13 Years","24 Years",{"count":22,"type":23},272,"ESTIMATED","INTERVENTIONAL",[26],"NA","The LYPS intervention is a multi-level intervention that combines: a) structural-level delivery of PrEP and PrEP services by a community health professional (CHP) at a designated place in the community being offered by the SC where PrEP is not yet provided (e.g., participant's home, community partner location, or traveling mobile van), with b) an individual-level mobile application (app) to support PrEP adherence and persistence between CHP visits.",[29,30,31],"HIV","PrEP","PrEP Adherence",[30,33,34,35],"Adherence","Oral PrEP","Injectable cabotegravir","NOT_YET_RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":23},"2026-07-27",{"date":44,"type":23},"2028-12-15",{"name":46,"class":47},"Westat","OTHER",4,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":17,"sex":55,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":4},"100614575","reducing-co-occurring-substance-use-and-hiv-risk-among-stimulant-using-men-at-high-risk-for-hiv-in-the-united-states-of-america-100614575","NCT07281378","Reducing Co-occurring Substance Use and HIV Risk Among Stimulant-using Men at High Risk for HIV in the United States of America.","Inclusion Criteria:\n\n1. be 18 years of age or older;\n2. be sexually active cisgender men at high risk for HIV (foreign and US-born, residing in the US)-reporting any condomless anal sex (CAS) in the past three months with a man;\n3. report use of stimulant (i.e., methamphetamine, powder cocaine, or crack-cocaine) at least one day in the past three or six month;\n4. have HIV-negative serostatus;\n5. be bilingual (Spanish and English), or Spanish or English monolingual;\n6. meet CDC criteria for PrEP eligibility.\n\nExclusion Criteria:\n\n1. display diminished capacity to consent (e.g., cognitive impairment); or\n2. severe psychiatric symptoms (e.g., psychosis) that require more intensive treatment;\n3. if they are HIV positive or living with HIV;\n4. if they are already taking PrEP; and\n5. if the participant can't consent to participate in English or Spanish.","MALE","18 Years",{"count":58,"type":23},84,[26],"This intervention will focus on stimulant-using men at high risk for HIV who are in need of tailored behavioral interventions to mitigate co-occurring stimulant use and HIV risk in the era of pre-exposure prophylaxis (PrEP). The study is a pilot randomized controlled trial to evaluate the adaptation, feasibility, acceptability, and preliminary efficacy of a behavioral intervention.",[62,63,31,64],"Drug Use Disorders","PrEP Uptake","HIV Risk Behavior",[30,66,29,67,68,69],"PrEP uptake","substance use","stimulant use","men at high risk for HIV","2026-06-29",{"date":72,"type":40},"2026-06-30",{"date":74,"type":23},"2026-07-20",{"date":76,"type":23},"2027-12-31",{"name":78,"class":47},"University of Florida",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":17,"sex":87,"minAge":4,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":90,"briefSummary":92,"conditions":93,"keywords":96,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":115},"100586764","phase-3-sti-testing-to-enhance-prep-use-in-pregnancy-100586764","NCT06919614","STI Testing to Enhance PrEP Use in Pregnancy","Improving PrEP Outcomes Among Pregnant Women in Botswana With an Integrated STI Testing and PrEP Delivery Model","STEP-UP","Inclusion Criteria:\n\n* Pregnant and seeking antenatal care\n* Self-identifying as a cis-gender woman\n* Living without HIV\n* Not currently using PrEP\n* Planning to remain in the city\u002Ftown of enrolment until 9 months post-delivery.\n* Planning to receive antenatal and postnatal care in the city\u002Ftown of enrolment.\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Male gender\n* Not pregnant\n* Living with HIV\n* Currently using PrEP\n* Not planning to remain in the city\u002Ftown of enrolment until 9 months post-delivery\n* Not planning to receive antenatal and postnatal care in the city\u002Ftown to enrolment\n* Not able or willing to provide informed consent for participation","FEMALE",{"count":89,"type":23},600,[91],"PHASE3","The investigators are conducting a study in Botswana to see if offering STI testing along with expanded HIV prevention options (PrEP) helps more pregnant women start and continue using PrEP during and after pregnancy. Pregnant women (n=600) seeking antenatal care in Botswana will be enrolled and randomly assigned to receive the standard of care (standard STI assessment with no STI testing) versus STI testing for Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis during pregnancy and postpartum. The investigators' hypothesis is that providing STI testing alongside PrEP offer will encourage more women to start and continue using PrEP.",[31,94,95],"Sexually Transmitted Infections (STIs)","Pregnancy",[97,30,29,98,99,100,101,102,103,104,34],"Pregancy","STIs","Chlamydia","Gonorrhoea","Gonorrhea","Trichomonas","Dapivirine","Truvada","RECRUITING","2026-06-09",{"date":108,"type":40},"2026-06-11",{"date":110,"type":40},"2025-06-18",{"date":112,"type":23},"2029-08-31",{"name":114,"class":47},"Botswana Harvard AIDS Institute Partnership",1,{"id":117,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":118,"targetDuration":4,"studyType":24,"phases":119,"briefSummary":27,"conditions":120,"keywords":121,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":48},"100626623",{"count":22,"type":23},[26],[29,30,31],[30,33,34,35],"2026-04-15",{"date":124,"type":40},"2026-04-16",{"date":126,"type":23},"2026-05",{"date":128,"type":23},"2028-12",{"name":46,"class":47},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":24,"phases":139,"briefSummary":140,"conditions":141,"keywords":144,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100632141","evaluation-of-mhealth-intervention-to-promote-hiv-prevention-and-overcome-stigma-among-transgender-women-empowher-100632141","NCT07509827","Evaluation of mHealth Intervention to Promote HIV Prevention and Overcome Stigma Among Transgender Women (EMPOW.HER)","Inclusion Criteria:\n\n* Age 18-29 years\n* Male sex at birth\n* Self-identify as transgender woman\u002Ffemale spectrum\n* HIV-negative (laboratory confirmed)\n* Recent condomless sex\n* Able to understand Thai\n* Not on PrEP or poorly adherent (≤3 pills\u002Fweek)\n\nExclusion Criteria:\n\n* Serious cognitive or psychiatric condition affecting consent\n* Active suicidal ideation or major mental illness\n* Medical contraindications to PrEP\n* Enrolled in another HIV intervention study","29 Years",{"count":138,"type":23},108,[26],"This study aims to develop and evaluate a multi-component mHealth intervention (mHC and FRESH) to reduce HIV-related and intersectional stigma and improve PrEP use among HIV-negative young transgender women (TGW) in Thailand.",[142,143,31],"HIV Prevention","HIV Related Stigma",[145,30,146],"mHealth","HIV stigma","2026-03-29",{"date":149,"type":40},"2026-04-03",{"date":151,"type":40},"2024-08-01",{"date":153,"type":23},"2028-07-31",{"name":155,"class":47},"Institute of HIV Research and Innovation Foundation, Thailand",3,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100622558","care-comprehensive-assessment-of-real-world-effectiveness-of-ftaf-in-persons-who-use-drugs-pwud-100622558","NCT07385183","CARE: Comprehensive Assessment of Real-world Effectiveness of F\u002FTAF in Persons Who Use Drugs (PWUD)","CARE","Inclusion Criteria:\n\n* Prep Initiation Inclusion: 18 years of age or older; Communicate in English; Confirmatory test of HIV-negative; Documented or identified history of injection drug use within the last six-months or have documented or identified general drug use within the last twelve months; Be able to provide at least one contact person including name and phone number where participant can be reached for follow-up\n* Clinician Interview Inclusion: At least 18 years of age; Healthcare provider or peer navigator, a person with lived experience in substance use disorder who will help navigate the patient through care, currently employed in TGH ED\n* Interview Inclusion: At least 18 years of age; Communicate in English; Confirmatory test of HIV-negative; Documented or identified history of injection drug use within the last six-months or have documented or identified general drug use within the last twelve months;\n\nExclusion Criteria:\n\n* PrEP Initiation Exclusion: Under 18 years of age; Determined to be HIV-positive following confirmatory testing; Have a CrCl of less than 30ml\u002Fmin, making them only eligible for long-acting injectable PrEP if CrCl is a limiting factor for oral PrEP; Have significant cognitive or developmental impairment to the extent that they are unable to provide informed consent; Are currently incarcerated or have pending legal action that may prevent an individual from completing the study; Pregnant.\n* Clinician Interview Exclusion: Under 18 years of age; Not currently employed as a healthcare provider or peer navigator in the TGH ED.\n* Interview Exclusion: Under 18 years of age; Have significant cognitive or developmental impairment to the extent that they are unable to provide informed consent; Are currently incarcerated or have pending legal action that may prevent an individual from completing the study;",{"count":165,"type":23},200,"OBSERVATIONAL","This study looks at how to help people who use drugs start and keep taking medicine that can prevent HIV. The medicine is called PrEP (pre-exposure prophylaxis). The study investigators will use a pill called Descovy (F\u002FTAF), which is already approved by the FDA for HIV prevention.\n\nPeople who come to the emergency department (ED) and test negative for HIV may join the study. Some participants will start taking PrEP and will be followed for one year. Other participants will only do an interview about their thoughts on PrEP. The study investigators will also talk to doctors and peer support workers in the ED to learn what makes it easier or harder to offer PrEP.\n\nThe main goal is to see how well PrEP can be started and continued for people who use drugs. The study investigators will look at how many people start PrEP, how many keep taking it, and what helps or makes it hard to stay on PrEP. The study investigators will also learn about the best ways to connect people to care after they leave the ED.\n\nThis study does not test if the medicine works to prevent HIV-that is already known. Instead, it looks at real-life challenges and solutions for using PrEP in this group. The study may help improve HIV prevention and health care for people who use drugs.",[169,31],"People Who Inject Drugs",[30,171],"People who Use\u002FInject Drugs","2026-01-26",{"date":174,"type":40},"2026-02-03",{"date":176,"type":23},"2026-02",{"date":178,"type":23},"2027-08",{"name":180,"class":47},"Heather Henderson",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":55,"minAge":56,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":24,"phases":191,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":115},"100609336","champion-combining-hiv-and-meth-prevention-and-treatment-interventions-optimized-for-hiv-negative-msm-100609336","NCT07213258","CHAMPION: Combining HIV And Meth Prevention and Treatment Interventions Optimized for HIV-Negative MSM","CHAMPION","Inclusion Criteria:\n\n1. HIV-negative\n2. Cis-gender male\n3. Age 18-40 years old\n4. Mild or moderate MUD (by DSM-5 SCID criteria)\n5. Anal intercourse with one or more male partners in the past 6 months\n6. Started daily oral PrEP more than 30 days ago and self-reported not always taking PrEP as prescribed in the past 30 days (consistent with PrEP It! inclusion criteria)\n7. Willingness to participate in an mHealth study with a 6-month follow-up\n8. Residing in San Diego or San Francisco County\n\nExclusion Criteria:\n\n1. Residing outside of San Diego or San Francisco County\n2. Any condition that, in the principal investigator's judgment interferes with safe study participation or adherence to study procedures\n3. Not able\u002Fwilling to complete virtual\u002Fremote visits\n4. Not willing to learn to self-collect dried blood spots using a finger stick","40 Years",{"count":190,"type":23},100,[26],"The goal of this randomized controlled trial is to pilot test new mobile health (mHealth) interventions to improve PrEP adherence among HIV-negative men who have sex with men (MSM) with mild to moderate methamphetamine use disorder (MUD). The CHAMPION intervention combines two mHealth tools-PrEPAPP and CBT4CBT-to address both HIV prevention and MUD treatment needs in this population. The study's specific aims are:\n\n* To evaluate the feasibility and acceptability of the CHAMPION intervention based on treatment retention and engagement rates.\n* To examine the preliminary efficacy the CHAMPION intervention to improve PrEP adherence, as measured by dried blood spot (DBS) tests compared to the waitlist control group.",[31,194,29],"Methamphetamine Use Disorder",[196,197,198,199,200,201,202,145,203],"MSM","HIV Negative","mild MUD","moderate MUD","Methamphetamine Use Disorder (MUD)","CBT4CBT","PrEPAPP","Cognitive Behavioral Therapy","2025-10-07",{"date":206,"type":40},"2025-10-08",{"date":208,"type":23},"2025-10-22",{"date":210,"type":23},"2026-08-15",{"name":212,"class":47},"University of California, San Diego"]